New Potential Personalized Medicine Platform

p-medicine project, launched in February this year, is a 4-year Integrated project aiming at developing a new and state-of-the-art IT platform for personalized medicine. The researchers elaborated the first deliverables according to the agreed 'Description of Work', they identified and described motivated use case scenarios by underlining the p-medicine platform's end user needs and requirements.

"It is the purpose of p-medicine to deliver an architecture that will allow to drive medicine to more individualized treatments based on exploiting the vast amount of heterogeneous data of single patients by software, services, tools and models that will support physicians in decision making in their daily care of patients," said p-medicine project coordinator Prof. Dr. Norbert Graf, Director of the Department of Pediatric Oncology and Hematology, Saarland University (Germany).

"All presented use-case scenarios have been actively discussed and only the mutually agreed versions have been considered," added Prof. Graf, who helped elaborate the first project deliverables while contributing and coordinating the input from all project partners.

"Project partners demonstrated a strong commitment and an active enrolment. The p-medicine project is an interdisciplinary and collaborative research activity. One of the learnt lessons is: we are in the right direction with high skilled and experienced partners," concluded Prof. Graf.

In p-medicine 19 partners from 9 European countries and Japan have dedicated themselves to enable support and sustain new knowledge and innovative technologies to overcome current problems in clinical research and pave the way for a more individualized treatment of cancer. p-medicine unifies European experts in different fields (clinicians, biologists, IT-specialists, ethical and legal experts) to develop and exploit data and tools that support translational research in every aspect.

For further information, please visit:
http://www.p-medicine.eu

About p-medicine project
The European Integrated Project p-medicine is supported by the European Commission under the 7th Framework Programme, Grant agreement number 270089.

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...